Latham & Watkins Advises on BridgeBio’s US$500 Million Convertible Senior Notes Offering

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases, has announced the pricing of US$500 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. In connection with the offering, the company granted the initial purchasers an option to purchase up to an additional US$75 million aggregate principal amount of notes. The sale of the notes is expected to close on February 28, 2025, subject to customary closing conditions.

Latham & Watkins LLP represents the initial purchasers in the offering with a corporate team led by partners Greg Rodgers and Shayne Kennedy, with associates Ryan Gold, Greg Van Buiten, Andrew Bentz, and Steve Hess. Advice was also provided on tax matters by partners Elena Romanova, Aaron Bernstein, and Kirt Switzer.